Insmed Analyst Price Targets - Benzinga

Insmed Inc

INSMNASDAQ

Trade with Public

Trade with Public

$101.74

-3.49-3.32%

Últ. Act.: Oct 7, 4:08 PM

$101.71

-3.52-3.35%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Insmed Analyst Price Targets - Benzinga

Insmed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Insmed (INSM).

Price Target Range — 7 Quarters

Analyst Consensus — 21 Analysts

21Buy

Consensus RatingBuy# Analysts21Avg. Consensus PT$197Upside to Avg. PT+93.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$237→$207
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$188
Sep 15, 2026	Roth Capital	Adam Walsh	PT Cut	Buy	$212→$198
Aug 10, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$179→$175
Aug 10, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$185→$195
Aug 7, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$207→$205
Aug 7, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$161→$169
Aug 7, 2026	Evercore ISI Group	Josh Schimmer	PT Raise	Outperform	$160→$170
Jul 21, 2026	BMO Capital	Connor Mackay	Initiate	Outperform	$192
Jul 15, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$160→$161
Jul 10, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$207
Jun 22, 2026	Evercore ISI Group	Josh Schimmer	PT Cut	Outperform	$162→$160
Jun 8, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$180→$179
Jun 5, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$205→$195
May 14, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$205→$185
May 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$220→$205
May 8, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$177→$160
May 8, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$230→$226
Apr 17, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$212
Apr 14, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$212→$216

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Insmed, Lowers Price Target to $207

Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Insmed (NASDAQ:INSM) with a Buy and announces $188 price target.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198

Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195

Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.

Benzinga Newsdesk